Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Dennis Slamon, MD, PhD, UCLA Health, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer (NCT03701334), discussed the study's broad population and potential payer reactions. Interim findings from the study were presented at the 2023 Annual Meeting of the American Society of Clinical Oncology.
Transcript
What elements make this trial different from other studies in early breast cancer?
The biggest element that differentiates this trial from other trials is the inclusion of a broader population of these patients—in other words, patients with node-negative disease, patients with lower-stage disease. Some of the trials were really focused on high-risk patients. Are those the only patients that can benefit from the drug? Patients who have lower risk but are still at risk for having—as I said, 30% will have a recurrence 2 or 3 decades out—can those patients be benefited? Well, the trial is including those patients in the study.
If this treatment approach is used in real-world settings, do you feel payers will see value in the improved safety profile vs the longer treatment duration?
My sense is that it all depends on the data. If the data are strong enough and there is a survival advantage, I think payers would be hard pressed not to provide reimbursement for the drug. Clearly, drug pricing is important. And it should be rational in terms of what the drug costs are. But if it provides real value and really makes an impact both on quality of life and life itself, I think those drugs should be paid for.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More